Welcome to NLS-1 Pharma
We design affordable, safe and effective drugs to safeguard and empower the brain throughout all stages of life. Our aim is to improve quality of life and longevity. We are creating new approaches to treat mental and behavioral disorders, and to enhance cognitive function in healthy people.
Interview with Alex Zwyer, CEO of NLS-1 Pharma AG (NLS) at The London Stock Exchange Studios. You can see more info of NLS-1 Pharma on the media in our Press Room section
NLS-1 Pharma is awarded in "The 30 Fastest Growing Companies to Watch" by CIO Bulletin Magazine
NLS-1 Pharma Is Awarded “Best Quality of Life Improvement Pharmaceuticals Company – Central Europe” by Global Health & Pharma Magazine
A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD)
NLS-1 Pharma Presents Positive Phase 2 Study Results for Mazindol at APSARD
NLS-1 Pharma is very interested in hearing from you. Please find general contact information below.
NLS-1 PHARMA GROUP
Alter Postplatz 2
CH-6370 Stans NW
T: +41 41 618 80 00
F: +41 41 618 80 09